01—Abstract
Summary
Summary of the 10-Q filed May 1, 2025. Cited figures are marked; the original filing is the authoritative source.
HCA Healthcare's first quarter 2025 results showed solid top-line growth and earnings expansion.
Revenues rose 5.7% to $18.321 billiona from $17.339 billion, driven by a 3.1% increase in equivalent admissions and a 2.5% increase in revenue per equivalent admission. Net income attributable to HCA rose 1.2% to $1.610 billion, or $6.45 per diluted share, versus $5.93 a year earlier. The comparison is flattered by the prior-year quarter, which included $201 million of facility sale gains ($0.57 per diluted share), so underlying earnings growth was stronger than the headline suggests.
Pretax income increased 3.5%, and diluted share count fell about 7% (249.4 million vs. 268.0 million) due to heavy buybacks, which helped per-share results. Cash generation weakened meaningfully. Operating cash flow fell $818 million to $1.651 billionb, driven by a $1.157 billion negative swing in working capital, with accounts receivable rising to $11.1 billion and days revenue in receivables at 54.
Capital spending was $991 millionc, and HCA repurchased $2.5 billion of stock in the quarter, funded in part by new borrowings. Total debt increased to $44.6 billion, though the company refinanced its 2025 maturities and terminated several secured facilities in favor of an $8 billion unsecured revolver, with $7.8 billion available at quarter-end. Stockholders' deficit widened to $(438) million, a result of buybacks exceeding retained earnings, which is typical for a leveraged repurchaser but worth monitoring.
Management flagged several risks going forward, including possible restructuring or elimination of state Medicaid supplemental payment programs, expiration of enhanced ACA premium tax credits at the end of 2025, rising uninsured volumes in Texas and Florida, and inflation in other operating expenses. Planned 2025 capex of $5.0 to $5.2 billiond and the $8.3 billion remaining buyback authorization signal continued capital deployment.
02—Key points
Key Highlights
- Revenue grew 5.7% to $18.321 billion, with equivalent admissions up 3.1% and revenue per equivalent admission up 2.5%; same facility revenue also rose 5.7%.
- Diluted EPS was $6.45 versus $5.93, up about 8.8%, but the prior-year quarter included $0.57 per share of facility sale gains, so underlying growth was stronger.
- Operating cash flow fell 33% to $1.651 billion from $2.469 billion, mainly due to a $1.157 billion negative working capital swing; accounts receivable rose to $11.1 billion.
- HCA repurchased 7.76 million shares for about $2.5 billion in Q1 2025, reducing diluted shares by roughly 7% year over year; $8.26 billion of authorization remains.
- Total debt rose to $44.6 billion; HCA issued $5.25 billion of senior notes and refinanced its 2025 maturities, replacing secured facilities with an $8 billion unsecured revolver.
- Stockholders' deficit widened to $(438) million, reflecting buybacks and distributions exceeding earnings; interest expense rose 6.8% to $547 million.
- Management flagged policy risks, including potential restructuring of state Medicaid supplemental payments, expiring enhanced ACA subsidies after 2025, and inflationary pressure on other operating expenses.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 1, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $18.32B$17.34B | +5.7% |
| Operating Expenses | $15.99B$15.09B | +6.0% |
| Interest Expense | $547.00M$512.00M | +6.8% |
| Net Income | $1.61B$1.59B | +1.2% |
| EPS (Basic) | $6.52$6.01 | +8.5% |
| EPS (Diluted) | $6.45$5.93 | +8.8% |
| Shares Outstanding (Basic) | 246.94M264.44M | −6.6% |
| Shares Outstanding (Diluted) | 249.44M268.02M | −6.9% |
05—Questions
Frequently Asked Questions
Did HCA's underlying profitability improve in Q1 2025?
Yes, on an adjusted basis. Pretax income rose 3.5% to $2.327 billion, but the prior-year quarter included $201 million of facility sale gains. Excluding those gains, pretax income grew substantially more. Salaries and benefits fell to 43.6% of revenue from 44.4%, a margin tailwind, while other operating expenses rose slightly to 21.0% from 20.9%.
Why did operating cash flow decline so sharply?
Operating cash flow dropped $818 million to $1.651 billion, mainly from a $1.157 billion negative working capital swing. Accounts payable and accrued expense outflows of $1.0 billion were the largest factor, along with a $327 million rise in receivables. Management attributed the decline to working capital timing rather than a deterioration in net income, which increased.
How is HCA funding its share buybacks and capital spending given the higher debt?
HCA issued $5.25 billion of senior notes in February 2025 and used the proceeds to repay its unsecured credit facility and fund general purposes. Net debt issuance was about $1.56 billion in the quarter. Capex of $991 million and buybacks of $2.5 billion exceeded operating cash flow of $1.65 billion. Management expects to fund 2025 capex of $5.0 to $5.2 billion with internally generated and borrowed funds, so leverage and interest costs bear watching.
What are the main regulatory risks to HCA's revenue?
Medicaid supplemental payment programs are under government review, and some states requested changes during CMS renewals that could reduce or eliminate them; management cannot estimate the impact. Enhanced ACA premium tax credits are scheduled to expire at the end of 2025, which could increase uninsured volumes. Uninsured admissions in Texas and Florida represent 73% of HCA's uninsured admissions, concentrating this exposure.
Is the stockholders' deficit a concern for investors?
The deficit of $(438) million reflects cumulative buybacks and distributions exceeding retained earnings, not operating losses. Net income attributable to HCA was positive, and the company generates strong EBITDA. However, a negative equity position means reported book value offers little downside protection, and the balance sheet depends on continued access to debt markets and stable cash generation.
06—Continue